Trilaciclib to Protect Bone Marrow in Limited-Stage Small Cell Lung Cancer
Compares trilaciclib with placebo in adults with limited-stage small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Key facts
- Where
- Athens, Pireas, and Thessaloniki, GreeceSee the 5 sites
- Phase
- Phase 3
Where in Greece
- Henry Dunant Hospital CenterAthens, GreeceTaking people
- Metropolitan HospitalPireas, GreeceTaking people
- Athens Medical Center S.A.Thessaloniki, GreeceTaking people
- Genesis Idiotiki Geniki Maieftiki Gynaikologiki Kliniki S.A.Thessaloniki, GreeceTaking people
- St. Luke's Hospital S.A.Thessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pharmacosmos A/S
- Trial code
- NCT07473128EU 2025-525026-35-00
- Record updated
- 2 October 2026
- Original description
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:Read full original descriptionShow less
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.
Inclusion: Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer; Complete recovery from prior anti-tumor surgical procedures; Measurable and evaluable disease through tumor assessment; Willingness to participate and sign informed consent form.
Exclusion: Extensive Stage Small Cell Lung Cancer; Active cardiovascular disease; Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations; Pregnant or nursing women.